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Abstract
Epstein-Barr virus (EBV) is a human lymphocryptovirus that is associated with several malignancies. Elevated EBV DNA in the
blood is observed in transplant recipients prior to, and at the time of post-transplant lymphoproliferative disease; thus, a
vaccine that either prevents EBV infection or lowers the viral load might reduce certain EBV malignancies. Two major
approaches have been suggested for an EBV vaccine- immunization with either EBV glycoprotein 350 (gp350) or EBV latency
proteins (e.g. EBV nuclear antigens [EBNAs]). No comparative trials, however, have been performed. Rhesus
lymphocryptovirus (LCV) encodes a homolog for each gene in EBV and infection of monkeys reproduces the clinical,
immunologic, and virologic features of both acute and latent EBV infection. We vaccinated rhesus monkeys at 0, 4 and 12
weeks with (a) soluble rhesus LCV gp350, (b) virus-like replicon particles (VRPs) expressing rhesus LCV gp350, (c) VRPs
expressing rhesus LCV gp350, EBNA-3A, and EBNA-3B, or (d) PBS. Animals vaccinated with soluble gp350 produced higher
levels of antibody to the glycoprotein than those vaccinated with VRPs expressing gp350. Animals vaccinated with VRPs
expressing EBNA-3A and EBNA-3B developed LCV-specific CD4 and CD8 T cell immunity to these proteins, while VRPs
expressing gp350 did not induce detectable T cell immunity to gp350. After challenge with rhesus LCV, animals vaccinated
with soluble rhesus LCV gp350 had the best level of protection against infection based on seroconversion, viral DNA, and
viral RNA in the blood after challenge. Surprisingly, animals vaccinated with gp350 that became infected had the lowest LCV
DNA loads in the blood at 23 months after challenge. These studies indicate that gp350 is critical for both protection against
infection with rhesus LCV and for reducing the viral load in animals that become infected after challenge. Our results
suggest that additional trials with soluble EBV gp350 alone, or in combination with other EBV proteins, should be
considered to reduce EBV infection or virus-associated malignancies in humans.
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Introduction
Epstein-Barr virus (EBV) is a causative agent of infectious
mononucleosis and is associated with a number of malignancies
including lymphomas in immunocompromised persons, Hodgkin
lymphoma, Burkitt lymphoma, and nasopharyngeal carcinoma.
Currently no vaccine has been licensed to prevent EBV infection
or disease.
Most attempts to generate an EBV vaccine have focused on
glycoprotein 350 (gp350) as the immunogen. gp350 is the most
abundant EBV glycoprotein in virions and on the surface of infected
cells.gp350bindstoCD21,the EBV receptoronB cells.EBV gp350
is spliced to formgp220.gp350 is important for virus absorption to B
cells and soluble gp350 can block EBV infection. Antibodies to
gp350 neutralize virus in vitro [1]. EBV gp350 protects cottontop
marmosets from B cell lymphomas when challenged with high titers
of EBV [2]. Numerous studies have shown that gp350 purified from
cells [3,4], expressed as a recombinant protein [5,6], or expressed
from an adenovirus [7] or vaccinia vector [8] can protect marmosets
from EBV lymphomas. Vaccinia virus expressing gp350 induced
EBV neutralizing antibody in seronegative children and a showed a
trend toward protection from EBV infection [9]. Vaccination of
young adults with recombinant gp350 in alum/monophosphoryl
lipid A induced EBV neutralizing antibodies and protected EBV
seronegative volunteers from infectious mononucleosis, but not from
EBV infection [10,11].
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mononucleosis, EBV proteins expressed during latency are
thought to be critical for controlling latent infection. The EBV
nuclear antigen 3 (EBNA-3) latency proteins are the primary
targets of CD8 T cells in the blood of healthy EBV carriers [12].
The success of treating patients with EBV lymphoproliferative
disease with infusions of EBV-specific T cells [13,14], in which the
EBNA-3 proteins represent the immunodominant epitopes,
indicates the critical role of these viral proteins for protection
from EBV disease. The importance of T cell responses to EBNA-
3B was demonstrated in a patient who died from an EBV
lymphoma after the tumor cells developed a large deletion in
EBNA-3B which allowed the malignant cells to escape from EBV-
specific cytotoxic T cells [15]. A peptide corresponding to EBNA-
3A was used in a small vaccine trial in EBV-seronegative human
volunteers [16].
Given the complexities and costs of EBV vaccine trials in
humans, testing vaccines in animal models might allow more
rapid comparison of candidate vaccines. Many animal studies
using gp350 have been performed in cottontop tamarins, which
have several limitations. These animals cannot be infected with
EBV by the oral route, they do not develop a persistent infection
similar to humans, and the animals do not express MHC class I
A, B or C alleles [17] which have been associated with virus-
specific cytotoxic T cells (CTLs). In contrast, rhesus lympho-
cryptovirus (LCV) is naturally endemic in rhesus monkeys and
reproduces most, if not all, of the features of EBV in these
animals [18]. Infection of monkeys with rhesus LCV results in
lymphadenopathy, splenomegaly, and atypical lymphocytes in
some animals, and animals shed the virus from the oropharynx
[19]. Unlike infection of cottontop tamarins with EBV, rhesus
monkeys can be infected orally with rhesus LCV and the animals
develop a persistent infection similar to that which occurs in
humans. When animals are immunosuppressed some develop B
cell lymphomas that contain rhesus LCV [20]. Rhesus LCV has
an ortholog for each of the EBV genes; conversely each EBV
gene has an ortholog in rhesus LCV [21]. The rhesus LCV genes
can complement their human EBV orthologs in nearly all
activities; thus, rhesus LCV should be an excellent model for
studying EBV pathogenesis.
While EBV gp350 has been shown to be protective against
tumors in cottontop tamarins challenged with high titers of EBV
and one study showed that gp350 reduced the incidence of
infectious mononucleosis in humans, no vaccine studies have been
performed using rhesus LCV in monkeys. Furthermore no studies
have been reported involving a direct comparison of different EBV
vaccines, including gp350 versus EBV latency proteins, in the
same trial.
We compared three rhesus LCV vaccines- (a) recombinant
soluble rhesus LCV gp350, (b) rhesus LCV gp350 expressed from
replication-defective, single cycle, virus-like replicon particles
(VRPs) derived from an attenuated strain of Venezuelan equine
encephalitis (VEE), and (c) a combination of rhesus LCV gp350,
EBNA-3A, and EBNA-3B each expressed in separate attenuated
VRPs for their ability to protect rhesus monkeys against infection
with rhesus LCV and to determine their long term effect on rhesus
LCV DNA in the blood after challenge.
Materials and Methods
Ethics statement
These experiments were approved by the Animal Care and Use
Committees of the National Institute of Allergy and Infectious
Diseases and the University of California, Davis. The studies were
carried out in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health.
Animals
Rhesus macaques were reared separately from rhesus LCV
seropositive animals beginning at birth and serologic testing
indicated that all animals were seronegative for rhesus LCV. Six to
18 month old animals were housed in pairs during the vaccination
period, and housed separately after challenge. Animals were
vaccinated by inoculation in the triceps muscle, and challenged
with rhesus LCV by inoculation of the back of the throat with
virus in 1 ml of cell culture media using a needleless syringe.
Viruses
Rhesus LCV was isolated from LCL8664 cells (American Type
Culture Collection, Manassas, VA). The cells were derived from a
rhesus monkey with a malignant lymphoma [22]. LCL8664 cells
were transfected with a plasmid expressing EBV BZLF1 using
electroporation as described previously [23], and after 5 days the
cells were pelleted and virus was isolated as reported previously
[24]. Rhesus LCV was titrated as previously described for human
EBV [25]. Briefly, serial dilutions of virus were incubated with
1610
5 rhesus peripheral blood mononuclear cells (PBMCs) and
the cells were plated into wells of a 96 well plate with 0.5 ug/ml of
cyclosporine A. After 6 weeks the titer of virus was determined by
the method of Reed and Muench [26].
Modified vaccinia Ankara (MVA) expressing rhesus LCV gp350
and green fluorescent protein (GFP) was constructed by cloning
rhesusLCVgp350 into plasmid pLW44 [27]. This plasmid contains
the GFP gene linked to the vaccinia virus p11 promoter to facilitate
screening of recombinant MVA. Due to a vaccinia transcription
terminationsignal[28]inthe rhesusLCVgp350gene (TTTTTGT,
sequence position 1147 to 1153), the 59 half of the gene (1-1,291)
was amplified by PCR using primers 59-TCCCCCCGGGAA-
CAATGGAAGCGGCTTTTCTG-39 and 59-ATACGCGTCGA
CTCTTCGGGTTGTCTGGTTGGAGC-39 (Xma I and Sal I
sites are underlined), and the PCRproduct was digested with Xma I
Author Summary
Epstein-Barr virus (EBV) is the primary cause of infectious
mononucleosis and is associated with several cancers.
Presently there is no licensed vaccine to prevent EBV
diseases. Two types of candidate vaccines are under
development; one involves immunization with the major
glycoprotein (gp350) on the outside of the virus, while the
other involves vaccination with EBV proteins expressed
during latency. We compared these two types of candidate
vaccines in a rhesus monkey model of EBV and found that
the gp350 vaccine induced better protection from
infection. In addition, animals that received the rhesus
EBV glycoprotein and became infected had a lower level of
rhesus EBV DNA in the blood at 23 months after challenge
than animals that received the rhesus EBV latency protein
vaccine that subsequently were infected. Since levels of
EBV DNA in the blood have been predictive for EBV
lymphomas in transplant patients, the ability of rhesus EBV
gp350 to reduce levels of rhesus EBV in the blood after
infection suggests the EBV gp350 could have a role in
reducing certain EBV-associated cancers. This is the first
test of candidate vaccines in the rhesus monkey model of
EBV and shows that this model should be useful in further
evaluation of EBV vaccines.
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plasmid pLW44. The T at nucleotide 1147 was changed to C
(resulting in no change in the amino acid sequence of gp350) using
the Quick Change Site-Directed Mutagenesis kit (Stratagene) and
the resulting plasmid was referred to as pLWrhgp350-mA. After
confirmation of the sequence, the 39 half of the gene was amplified
using primers 59-TCCCCCCGGGGCAGCCACAAATGTCAC-
CGCTGTT-39 and 59-ATACGCGTCGACCTAAACAGCGG-
TTTCAAATTC -39 (Xma I and Sal I sites underlined). The
resulting PCR product was cut with XmaI and Sal I and inserted
into the corresponding site of pLW44 to obtain plasmid
pLWrhgp350-B. pLWrhgp350-mA was cut with Not I and Sex
AI and the 59 end of rhesus LCV gp350 was inserted into the Not I
and Sex AI sites of pLWgp350-B to yield plasmid
pLWrhgp350GFP. DF-1 (a chicken embryo fibroblast cell line) or
primary chicken fibroblasts (a gift from Linda Wyatt, NIH) were
infected with 0.05 plaque forming units (pfu) of MVA per cell and
2 hours later the cells were transfected with plasmid
pLWrhgp350GFP. Plaques expressing GFP and rhesus LCV
gp350 were isolated by successive rounds of plaque purification
by freeze-thawing cells containing GFP-positive plaques and plating
at limiting dilutions. The resulting virus, named MVA-gp350GFP,
was propagated in DF-1 cells. To obtain MVA expressing rhesus
LCV without GFP, plasmid pLWrhgp350GFP was digested with
Kpn I which removes the GFP gene and religated to yield
pLWrhgp350. DF-1 cells were infected with MVA-gp350GFP and
2 hours later were transfected with pLWrhgp350. Plaques that did
not express GFP were isolated by plaque purification and the
resulting virus was named MVA-gp350.
Plasmids
gp350 constructs. The extracellular domain of rhesus LCV
gp350 (amino acids 1–737 [21]) was cloned by PCR amplification
using DNA isolated from LCL8664 cells and primers rhgp350-
Sal (59ATACGCGTCGACAACAATGGAAGCGGCTTTTC-
TG -39) which contains a Sal I site (underlined) and rhgp350-
TM-BglRv (59-G A AGATCTTAGCATGGAGAGATTGGAG-
CCCTC-39) which contains a Bgl II site (underlined). To
construct a plasmid expressing rhesus LCV gp350 in cell
culture, the PCR product containing the extracellular domain
of rhesus LV gp350 was digested with Sal I and Bgl II and used as
part of a three fragment ligation along with the Bgl II-Not I
fragment of human Fc (derived from pDC409 [29]) and the Sal I-
Not I fragment of pDC409. The resulting plasmid, pDCrhgp350-
Fc, expresses the extracellular domain of rhesus LCV gp350 fused
to the Fc domain of human IgG.
To construct pSGrhgp350, the rhesus LCV gp350 gene was
amplifiedfrom LCL8664 cell DNAby PCRusingprimers rhgp350-
F-EcoR containing an EcoR I site (CCGGAATTCAACAATG-
GAAGCGGCTTTTCTG) and rhgp350-BglRv (59- CGCAGAT-
CTCTAAACAGCGGTTTCAAATTCATCATC-39) containing
a Bgl II site (underlined) and inserted into the corresponding sites
of pSG5 vector (Stratagene). To obtain pCIrhgp350, pSGrhgp350
was digested with Bgl II, blunted using T4 DNA polymerase, cut
with EcoR I and the gp350 gene was cloned into the EcoR I-Sma I
sites of pCI (Promega).
To measure antibody to rhesus LCV gp350, a plasmid was
constructed containing the viral gene linked to the Renilla luciferase
gene. The extracellular domain of the rhesus LCV gp350 gene was
amplified by PCR using primers rhgp350-F-EcoR (see above) and
rhgp350-TMR (59-A A A GAATTCTAGCATGGAGAGATTG-
GAGCCCTC -39) with an EcoR I site (underlined). The PCR
product was digested with EcoR I and cloned into the correspond-
ing EcoR I site of pREN3S to generate plasmid pREN3rhgp350.
EBNA-3 constructs. Since Jiang et al. [30] reported that
rhesus LCV EBNA 3A begins at nucleotide 73,492, while Rivailler
et al. [31] stated that the protein starts at nucleotide 73,534, we
produced constructs expressing the former termed rhEBNA3A1
(in which EBNA-3A would start at the first methionine) and the
latter termed rhEBNA3A2 (in which EBNA-3A would start at the
second methionine). Rhesus LCV EBNA-3A1 was amplified from
cDNA (since EBNA-3A mRNA is spliced near its 59end) after
RNA had been isolated from LCL8664 cells and cloned into TA-
cloning vector pCR2.1 using the TOPO TA cloning kit
(Invitrogen) and primers rhEBNA3A-FSal (59- ACCGT-
CGACAAAATGGAGGAAGAAAGGCCG-39) or rhEBNA3A2-
FSal (59-ACCGTCGACAACATGGAAGAAGAGGAGGTT-
CCATCC-39) containing a Sal I site (underlined) and
rhEBNA3A-RPst (59-ACCCTGCAGTTATTCCTCATTATCT-
GGGGGATC-39) with a Pst I site (underlined). Due to mutations
in the 39 portion in the cDNA noted after cloning, rhEBNA-3A1
was also amplified from DNA obtained from LCL8664 cells using
same primers described above. The PCR product was then cut
with Sal I and Pst I and inserted into the corresponding site of
pLW44. To construct EBNA-3A1 and EBNA-3A2 without an
intron, a three-fragment ligation was performed using (a) a Sal I-
Pfo I fragment from the 59 end of the EBNA-3A cDNA, (b) a Pfo I-
Pst I fragment of EBNA-3A DNA, and (c) a Sal I-Pst I fragment
from pLW44. The resulting plasmids were termed pLWrhEBNA-
3A1 and pLWrhEBNA-3A2.
To clone EBNA-3A1 and EBNA-3A2 into an SV40 expression
vector, PCR was performed with primer rhEBNA3A-FBcl 59-
ACCTGATCAAAAATGGAGGAAGAAAGGCCG-39 or rhEB-
NA3A2FBcl 59-ACCTGATCAAACATGGAAGAAGAGGAG-
GTTCCATCC-39 with a Bcl I site (underlined) and rhEB-
NA3A-RBcl 59-ACCTGATCATTATTCCTCATTATCTGGG-
GGATC-39 with a Bcl I site (underlined) using plasmid
pLWrhEBNA-3A as a template. The PCR products were cut
with Bcl I and cloned into the Bam HI site of pSG5 to obtain
pSGrhEBNA3A1 and pSGrhEBNA3A2.
To clone EBNA-3A1 into a CMV expression vector,
pLWrhEBNA3A was digested with Pst I, blunted with T4 DNA
polymerase, digested with Sal I, and the fragment containing
EBNA-3A was inserted into the Sal I-Sma I site of pCI to produce
pCIrhEBNA3A.
Rhesus LCV EBNA-3B was amplified from LCL8664 cell DNA
as two separate fragments using primer pairs rhEBNA3BF-Sal
(59- ACCGTCGACAAAATGAAGAAAGCTTGGCTCGGC-39)
and rhEBNA3B GCR-Pst (59-ACCCTGCAGTGGGGCAGCT-
GATATGGGGCGGCTCGC-39 to generate the 59 end of
EBNA-3B), and primer pairs rhEBNA3B GCF-Sal (59- ACAGTC-
GACACCCCCCGGGCACATATACCCGCCA-39) and rhEB-
NA3BR-Pst (59- ACCCTGCAGTTAGAACTCCTCGTCCGA-
TATTTC-39) to generate the 39 end of EBNA-3B (Sal I and Pst I
sites underlined). The 59 EBNA-3B PCR product was cloned using
the Invitrogen Zero Blunt TOPO PCR Cloning kit to generate
pBluntrhEBNA3B-59 and the 39 EBNA-3B PCR product was
cloned using the Invitrogen TOPO TA PCR Cloning kit to
generate pCRrhEBNA3B-39. The spliced region of rhesus LCV
EBNA3B was amplified from cDNA obtained from RNA of
LCL8664 cells using primers rhEBNA3BF-Sal and rhEB-
NA3BspR-Pst (59- AAACTGCAGTATGACGCACAGTCATG-
CAGAGCC-39; Pst I site underlined) and cloned using the
Invitrogen Zero Blunt TOPO PCR Cloning Kit to obtain
pBluntrhEBNA3B-spA. To produce a full length spliced EBNA-
3B gene, a 3 fragment ligation was performed using (a) the Sal I-
Bsa BI fragment containing the 59 spliced end of EBNA-3B
derived from pBluntrhEBNA3B-spA, (b) the Bsa BI-Xma I
Rhesus LCV Vaccine Protects and Reduces Virus Load
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pBluntrhEBNA3B-59, and (c) the large Sal I-Xma I fragment
containing the 39 end of EBNA-3B and the plasmid vector derived
from pCRrhEBNA3B-39. The resulting plasmid, pCRrhEBNA3B,
contains the full length spliced form of rhesus LCV EBNA-3B.
To clone EBNA-3B into a SV40 expressing vector, EBNA-3B
was removed from plasmid pCRrhEBNA3B by digestion with Sal
I and Pst I, the ends were blunted using T4 DNA polymerase and
the EBNA-3B gene was inserted into the Bam HI site of plasmid
pSG5 (after blunting with the Klenow fragment of DNA
polymerase I) to obtain pSGrhEBNA3B. To clone EBNA-3B into
a CMV expression vector, EBNA-3B was removed from plasmid
pCRrhEBNA3B by digestion with Sal I and Not I and inserted
into the corresponding sites of pCI to obtain pCIrhEBNA3B.
To remove the RBP-Jk binding sites from rhEBNA-3A1 we
deleted codons 204–207 (TFAC) corresponding to nucleotides
610–621 from pSGrhEBNA3A1. To remove the RBP-Jk binding
sites from rhEBNA-3B, we deleted codons 208 to 211 (TLGC)
corresponding to nucleotides 622–633 from pSGrhEBNA3B using
the Quik Change site-directed Mutagenesis kit (Stratagene). The
resulting plasmids deleted for the EBNA-3 RBP-Jk binding sites,
pSGrhEBNA3A1-del, pSGrhEBNA3A2-del, and pSGrhEB-
NA3B-del, were only used for cloning into the Venezuelan equine
encephalitis vector (see below). All gp350, EBNA-3A, and EBNA-
3B constructs obtained by PCR were sequenced.
Recombinant proteins
To produce rhesus LCV gp350-Fc protein, CV-1/EBNA-1 cells
(ATCC, Manassas, VA) grown in DMEM/F-12 medium (1:1)
with 10% fetal bovine serum, were transfected with plasmid
pDCrhgp350-Fc using DEAE-Dextran. After transfection, the
media was changed to DMEM/F12 medium with 0.5% low
immunoglobulin G fetal bovine sera (HyClone, Logan, UT). One
week after transfection, the media was collected, clarified by low
speed centrifugation, and filtered through a 0.45 um filter.
Recombinant rhesus LCV gp350-Fc was bound to protein A-
Sepharose beads, eluted from the beads with 12.5 mM citric acid
pH 2.2, and collected in tubes containing 500 mM HEPES,
pH 9.0 to neutralize the citric acid.
To produce recombinant rhesus LCV EBNA-3A and EBNA-
3B, Cos cells were transfected with plasmid pSGrhEBNA3A1 or
pSGrhEBNA3B using Lipofectamine 2000 (Invitrogen). Two days
after transfection, lysates were prepared from the cells and proteins
were separated by polyacrylamide gel electrophoresis. Proteins
were stained with Coomassie blue, and bands containing EBNA-
3A and EBNA-3B were excised from the gel. EBNA-3 proteins
were eluted from the gel overnight in PBS and concentrated using
a Centricon YM-100 filter (Millipore).
Antibodies
To produce antibody to rhesus LCV gp350, 2 rabbits were
immunized with 150 ug of rhesus LCV gp350-Fc fusion protein in
complete Freund’s adjuvant (Animal Pharm Service Inc.,
Sausalito, CA). Animals were boosted with 100 ug of gp350-Fc
in incomplete Freund’s adjuvant on days 28, 42, and 86 after the
first vaccination; 2 weeks after the last boost the rabbits were bled
and sera were obtained.
To produce antibody to rhesus LCV EBNA-3A and EBNA-3B,
mice were immunized three times, 3 weeks apart with 100 ug of
pCIrhEBNA3A or pCIrhEBNA3B. Three weeks after the 3rd
DNA immunization, the animals were boosted with 20 ug of
EBNA-3A protein or 15 ug of EBNA-3B protein in complete
Freund’s adjuvant. Serum was collected from the mice 2 weeks
later.
Vaccines
For rhesus monkey vaccinations, rhesus LCV gp350-Fc protein
was incubated with Alhydrogel 2% (Brenntag Biosector, Accurate
Chemical and Scientific Corp) by mixing on a rotating wheel for
30 min at room temperature followed by addition of monopho-
sphoryl lipid A (Avanti Polar Lipids, Inc., Alabaster, AL).
Replication-defective attenuated Venezuelan equine encephali-
tis viruses (VEE) expressing rhesus LCV gp350, EBNA-3A1, or
EBNA-3B were constructed by PCR amplification of the genes
from plasmids pSGrhgp350, pSGrhEBNA3A1-del, pSGrhEB-
NA3B-del and inserting the rhesus LCV genes into a VEE
replicon vector. The replicon vector contains the VEE nsP1, nsP2,
nsP3, and nsP4 genes and an internal ribosome entry site (IRES)
followed by a cloning site into which the rhesus LCV genes were
inserted [32]. RNAs were produced from the replicon and VEE
plasmid vectors using T7 polymerase. Vero cells were co-
transfected with (a) helper RNA expressing VEE capsid, (b) helper
RNA expressing VEE glycoprotein [33], and (c) RNA obtained
from replicon vectors expressing rhesus LCV gp350, EBNA-3A, or
EBNA-3B. The resulting transfections generated replication-
defective, single-cycle, virus-like replicon particles (VRPs) [32,34].
Antibody testing for rhesus LCV and for gp350
Antibody to rhesus LCV viral capsid antigen (VCA) was
determined by immunofluorescence (VRL Laboratories, San
Antonio, Texas).
Antibody to rhesus LCV gp350 was measured using the
luciferase immunoprecipitation system (LIPS) assay [25]. Cos cells
were transfected with pREN3rhgp350 which encodes a fusion
protein containing the rhesus LCV gp350 gene linked to the
Renilla luciferase gene. Activity in transfected Cos cell lysates was
determined by luminometry and expressed as luminometer units
(LU) per ml as described previously [25]. To measure rhesus LCV
gp350 antibody levels in animals, rhesus monkey plasma were
diluted 1:10, and 1 ul was added to 1610
7 light units (LU) of
transfected Cos cell extract. Immunoprecipitations were per-
formed by addition of protein A/G beads, and LU were
determined by luminometry. A cut-off threshold limit was derived
from the mean value plus 2 standard deviations of the background
LU. All LU data shown represent the average of two independent
experiments.
Real-time PCR to quantify rhesus LCV DNA and RNA
DNA was isolated from 125610
6 PBMCs using either a
QIAamp DNA Blood Mini Kit (Qiagen) or an Easy-DNA Kit
(Invitrogen). Real time PCR for rhesus LCV DNA was performed
with primers and probes that amplify rhesus LCV EBER1 [35]
using the following conditions: 94uC for 15 sec, 60uC for 30 sec,
and 72uC for 35 sec for a total of 40 cycles. Real time PCR was
also performed to amplify the internal repeat 1 (IR1) region of
rhesus LCV (which corresponds to the EBV Bam HI W fragments)
with primers 59-AAATCTAAACTTTTGAGGCGATCTG-39
and 59-CCAACCATAGACCCGTTTCCT -39 and probe 59-(6-
Fam)-TCTCCGCGTGCGCATAATGGC-(TAM RA)-39 using
the following conditions: 50uC for 2 min and 94uC for 10 min
for 1 cycle, followed by 94uC for 15 sec, 60uC for 1 min, for 45
cycles. Viral DNA was normalized using GAPDH [31] and results
were expressed as DNA copies per 1610
6 PBMCs.
Real time reverse-transcriptase PCR was performed for rhesus
LCV EBER1. Total RNA was isolated from 5610
6 PBMCs using
Trizol (Invitrogen, Calsbad, CA), and reverse transcription and
PCR was performed using primers and probes as described
previously [35] and PCR conditions described above.
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Rhesus monkey cell lines were used topresentEBNA-3A, EBNA-
3B, and gp350 to rhesus PBMCs. Lymphoblastoid cell lines (LCLs),
which express EBNA-3A and EBNA-3B, were constructed for each
monkey by infecting PBMCs with rhesus LCV in the presence of
cyclosporine A (500 ng/mL, Sigma-Aldrich) and culturing the cells
in RPMI 1640 with GlutaMax (Invitrogen) with 10% FBS and
antibiotics. Cryopreserved PBMCs were thawed and cultured in
RPMI 1640 with GlutaMax with 10% FBS, IL-2 (5 U/mL, from
the National Cancer Institute) and antibiotics in 12-well plates
overnight. The following day, PBMCs were divided into 2 tubes
(123610
6 cells per tube) and were cocultured with 2610
6
autologous LCLs for 5 hours in the presence of 10 mg/mL of
brefeldin A (Sigma-Aldrich) and 10 U/mL of IL-2. The cells were
then washed in PBS with 2% FBS and 2 mM EDTA, incubated
with FITC-conjugated anti-CD8 monoclonal antibody (clone RPA-
T8, BioLegend, San Diego, CA) and APC-conjugated anti-CD4
monoclonalantibody (cloneOKT4,BioLegend) for20 min, washed
with PBS containing 2% FBS and 2 mM EDTA, incubated with
Cytofix/Cytoperm buffer (BD Bioscience, Franklin Lakes, NJ) for
25 min, and washed with Perm wash buffer (BD Bioscience). Cells
were then incubated with PE-conjugated anti-IL-2 monoclonal
antibody (clone MQ1-17H12, BioLegend) and PE-Cy7-conjugated
anti-IFN-c monoclonal antibody (clone B27, BD Bioscience),
washed with Permwash buffer, and resuspended in PBS with 2%
FBS and 2 mM EDTA. As a negative control, PBMCs were
cultured without LCLs, and mixed with LCLs after fixation of
PBMCs with Cytofix/Cytoperm buffer. Data were acquired using a
FACS Caliber (BD Bioscience) and analysis was performed using
Flowjo software 8.8.4 (Tree Star Inc., Ashland, OR). The percent of
rhesus LCV-specific cytokine T cell response was defined as the
percent cytokine (IL-2 or IFN-c, or both) positive CD4 or CD8 cells
in LCL-stimulated PBMCs minus the percent cytokine positive
CD4 or CD8 cells in unstimulated PBMCs. If unstimulated samples
had a higher frequency of cytokine positive cells than stimulated
samples, a value of 0% was assigned, instead of a negative value.
To measure gp350-specific CD8 and CD4 T cell responses,
LCLs were infected with either wild-type MVA, or MVA
expressing rhesus LCV gp350, at 3 TCID50 for 24 hours before
coculture with PBMCs. PBMCs were thawed and cultured
overnight as described above. The following day, PBMCs were
divided into 3 tubes (0.822610
6 cells per tube) and cocultured
with LCLs infected with either wild-type or gp350 expressing
MVA for 5 hours in the presence of brefeldin A. As a negative
control, PBMCs were cultured without LCLs and mixed with
LCLs (not infected with MVA) after fixation of PBMCs with
Cytofix/Cytoperm buffer. Staining and flow cytometry were done
as described above. The percent of cytokine producing CD4 or
CD8 cells in unstimulated PBMCs mixed with LCLs (not infected
with MVA) after fixation (negative control) was subtracted from
the percent of CD4 or CD8 cells in PBMCs stimulated with gp350
MVA-infected LCLs or wild-type MVA-infected LCLs. The
percent of rhesus LCV gp350-specific CD4 or CD8 T cell
response was defined as the percent of cytokine producing CD4 or
CD8 cells in PBMCs stimulated with gp350 MVA-infected LCLs
minus the percent of cytokine producing CD4 or CD8 cells in
PBMCs stimulated with wild-type MVA-infected LCLs.
Results
Antibody to rhesus LCV gp350 detects the glycoprotein
in cells infected with MVA-gp350
In order to determine if rhesus LCV encodes gp350 similar to its
human EBV homolog, rabbits were immunized with purified
rhesus LCV gp350-Fc fusion protein and serum was obtained. The
rabbit serum detected proteins from 2002270 kDa in supernatant
from cells transfected with plasmid expressing soluble gp350-Fc,
but not with plasmid expressing GFP (pGL3-GFP) (Fig. 1, lanes
1, 2).
To ensure that the rabbit antibody was specific for rhesus LCV
gp350, we determined that the antibody could detect full length
gp350 in virus-infected cells. Full length rhesus LCV gp350 was
inserted into modified vaccinia Ankara (MVA). DF-1 cells were
infected with MVA-gp350GFP or MVA alone and 16224 hr
later, lysates were prepared, and immunoblotted with the rabbit
serum. Cells infected with MVA-gp350GFP, but not MVA alone
produced a 250 kDa protein that reacted with the antibody
(Fig. 1, lanes 3, 4). Similarly, Cos cells infected with virus-like
replicon particles expressing rhesus LCV gp350 (VRP-gp350), but
not cells expressing GFP (VRP-GFP), expressed proteins of
2202250 kDa that reacted with the antibody (Fig. 1, lanes 5,
6). We were unable to detect rhesus LCV gp350 in LCL8664 cells
Figure 1. Detection of gp350 in supernatant from cells
transfected with a plasmid expressing soluble gp350, lysate
from DF-1 cells infected with MVA-gp350, and lysate from
Vero cells infected with VRP-gp350. Supernatant from cells
transfected with control plasmid pGL3-GFP, or lysates from cells
infected with MVA or VRP-GFP are negative controls.
doi:10.1371/journal.ppat.1002308.g001
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expressing EBV BZLF1 (data not shown), likely due to low levels of
the glycoprotein.
Sequence and expression of rhesus LCV EBNA-3A and
EBNA-3B
In order to express rhesus LCV EBNA-3A and EBNA-3B, we
cloned the genes from LCL8664 cells into expression vectors and
determined the sequence of the viral genes. While the sequence of
rhesus LCV EBNA-3A was identical to the published sequence
[21], the sequence of rhesus LCV EBNA-3B was different. We
found a T deleted at nucleotide 1744 and a C inserted at
nucleotide 2206 of rhesus LCV EBNA-3B. The deletion at
nucleotide 1744 results in a frameshift in the EBNA-3B sequence
beginning at codon 582, and the insertion at nucleotide 2206
restores the open reading frame to the published amino acid
sequence at codon 735 so that the last 193 amino acids of the
protein are unchanged (Fig. 2). This was verified for several PCR
clones from LCL8664 cells and by direct sequencing of DNA from
LCL8664 cells. Comparison of the amino acid sequence of rhesus
LCV EBNA-3B reported here, in the region just prior and after
the frameshift mutation (acids 5772740), with that of EBV AG876
EBNA-3B showed 31% identity, while comparison of the prior
rhesus LCV EBNA-3B sequence [21] with EBV AG876 EBNA-2B
showed only 16% identity. Taken together these findings suggest
that the sequence reported here for rhesus LCV EBNA-3B is more
likely to be the authentic sequence of the protein.
Both EBV EBNA-3A [36] and EBNA-3B bind to RBP-Jk and
stimulate B cell proliferation. Since EBV EBNA-3A is critical for B
cell growth transformation and survival [36] and EBNA-3-induced
B cell proliferation might be problematic for a vaccine, we deleted
the RBP-Jk binding sites in rhesus LCV EBNA-3A and EBNA-3B.
Figure 2. Alignment of amino acids 5772740 of rhesus LCV EBNA-3B from LCL8664 cells (middle lines) with the previously
published sequence ([21], lower lines), and amino acids 5712768 of EBV AG876 EBNA-3B (top lines). Numbers indicate amino acid
positions of rhesus LCV EBNA-3B and arrows indicate where the sequences of rhesus LCV EBNA-3B diverge and then return to identity.
doi:10.1371/journal.ppat.1002308.g002
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(amino acids 1992202), to AAGA results in loss of function of the
protein and reduces its ability to bind to RBP-Jk. Rhesus LCV
EBNA-3A and EBNA-3B also bind to RBP-Jk [30]. Alignment of
the amino acid sequence of rhesus LCV EBNA-3A with its EBV
homolog predicts that the rhesus LCV EBNA-3A RBP-Jk binding
site TFAC (amino acids 204 to 207 based on the sequence of Jiang
et al. [30], or amino acids 1902193 based on the sequence of
Rivailler et al. [31]) are positional homologs of the RBP-Jk binding
site TLGC (amino acids 1992202) of EBV EBNA-3A. Similarly,
alignment of rhesus LCV EBNA-3B with EBV EBNA-3B predicts
that amino acids 208 to 211 (TLGC) of rhesus LCV EBNA-3B are
positional homologs of EBV EBNA-3B amino acids 205 to 208
(TLGC). Therefore, we deleted these four codons from rhesus
LCV EBNA-3A and EBNA-3B in vectors expressing these genes.
Based on the sequence of rhesus LCV EBNA3A (rhEBNA3A),
either of two methionines could be the first amino acid of the
protein [30]. To determine which can be used for EBNA-3A, we
made four EBNA-3A constructs- rhEBNA-3A1 (which starts at the
first methionine), rhEBNA-3A2 (which starts at the second
methionine), rhEBNA-3A1-del and rhEBNA3A2-del (in which
the four amino acid putative RBP-Jk binding site in EBNA-3A was
deleted). Transfection of Cos cells with pSGrhEBNA3A1,
pSGrhEBNA3A2, pSGrhEBNA3A1-del, and rhEBNA3A2-del
followed by Coomassie blue staining of cell lysates in PAGE gels
showed bands of 147 kDa, 145 kDa, 147 kDa, and 144 kDa,
respectively (Fig. 3A, lanes 225). These studies indicate that
either the first or second methionine can be used for producing
EBNA-3A. Transfection of Cos cells with pSGrhEBNA3B or
pSGrhEBNA3B-del (deleted for the four amino acid putative RBJ-
k binding site) yielded a band of 150 kDa (Fig. 3A, lanes 6,7).
Vero cells infected with VRP-EBNA-3A showed predominant
bands of 102 and 88 kDa, while LCL8664 cells and rhesus LCV
LCL-V showed a band of about 102 kDa (Fig. 3B). Vero cells
infected with VRP-EBNA-3B showed an upper band of 145 kDa
and more intense bands from 1052120 kDa while LCL8664 cells
and rhesus LCV LCL-V showed a band of 145 kDa (Fig. 3C).
Recombinant soluble gp350 elicits higher antibody titers
to gp350 than VRP-gp350 in rhesus monkeys
Four rhesus LCV seronegative monkeys each received one of
four inocula intramuscularly: (a) 50 ug of rhesus LCV soluble
gp350-Fc protein (soluble gp350) formulated in 800 ug alum and
50 ug monophosphoryl lipid A, (b) 1610
8 infectious units (IU) of
virus-like replication-defective VEE particles expressing rhesus
LCV gp350 (VRP-gp350) in 1 ml of DMEM with 10% FBS, (c) a
combination of three separate replication-defective VEE particles
expressing rhesus LCV gp350 (VRP-gp350), EBNA-3A (VRP-
EBNA-3A), and EBNA-3B (VRP-EBNA-3B) each at a titer of
1610
8 IU in a total of 1 ml of DMEM with 10% FBS, or (d) PBS
control. The rhesus LCV soluble gp350 used in our vaccine
contains the extracellular domain of the glycoprotein fused to the
Fc domain of human IgG, while the vaccine used in the large
human trial [11] has the extracellular domain of EBV gp350 with
a mutation in the gp220 splice site and no Fc protein fused to the
glycoprotein. The alum/monophosphoryl lipid A adjuvant was
chosen for rhesus LCV soluble gp350, since this is the adjuvant
that was used in the large human EBV gp350 study [11]. Animals
were vaccinated at weeks 0, 4, and 12.
Serum antibody responses to gp350 in animals 5 weeks after the
last vaccination showed that all animals vaccinated with soluble
gp350 or VRP-gp350 (alone or in combination with VRPs
expressing EBNA-3A and EBNA-3B) produced antibodies to the
glycoprotein (Fig. 4). The geometric mean antibody level was
significantly higher in animals vaccinated with recombinant
soluble gp350 than in animals receiving VRP-gp350 (p,0.05) or
in animals that had been naturally infected with rhesus LCV
(p,0.05). The geometric mean antibody titer in animals receiving
VRP-gp350 (alone or in combination with VRPs expressing
EBNA-3A and EBNA-3B) was not significantly different than in
animals naturally infected with rhesus LCV.
Immunization of monkeys with VRPs expressing a
combination of EBNA-3A, EBNA-3B, and gp350 induces
rhesus LCV LCL-specific CD4 and CD8 T cell immune
responses
Rhesus LCV LCL-specific CD4 and CD8 T cell immune
responses in monkeys were measured both pre- and post-
vaccination. Rhesus LCV LCLs, which express EBNA-3A and
EBNA-3B (Fig. 3), from each monkey served as antigen presenting
cells. PBMCs from monkeys were incubated with autologous LCLs
and cells were then stained for surface expression of CD4 and CD8
and for intracellular expression of IL-2 and IFN-c. Before
vaccination, the mean percentage of rhesus LCV-specific cytokine
producing CD4 T cells was 0.001460.0013, 0.001360.0014,
0.014360.0135 and 0.007860.0045 (mean 6 SE) for animals
receiving PBS, soluble gp350, VRP-gp350, and combined VRP-
gp350, VRP-EBNA-3A, and VRP-EBNA-3B, respectively (Fig. 5).
The mean percentage of rhesus LCV-specific CD4 T cells after
vaccination was 0.014760.0165, 0.007060.0053, 0.046760.0500
and 0.089460.0516 for animals receiving PBS, soluble gp350,
VRP-gp350, and combined VRP-gp350, VRP-EBNA-3A, and
VRP-EBNA-3B,respectively.ThemeanpercentageofrhesusLCV-
specific cytokine producing CD8 T cells pre-vaccine was
0.011160.0105, 0.014060.0077, 0.033460.0194 and 0.02236
0.0178 for monkeys receiving PBS, soluble gp350, VRP-gp350, and
combined VRP-gp350, VRP-EBNA-3A, and VRP-EBNA-3B,
respectively. Post-vaccination, the mean percentage of rhesus
LCV-specific CD8 T cells was 0.031560.0117, 0.026060.0152,
0.039060.0185 and 0.183460.1059 for PBS, soluble gp350, VRP-
gp350, and combined VRP-gp350, VRP-EBNA-3A, and VRP-
EBNA-3B, respectively. While there was considerable variability
among individual animals, only animals receiving combined VRP-
gp350, VRP-EBNA-3A, and VRP-EBNA-3B had a statistically
significant increase in the percentage of rhesus LCV LCL-specific
CD4 T cells (p=0.032 by T-test). Animals that received combined
VRP-gp350, VRP-EBNA-3A, and VRP-EBNA-3B had an increase
in the percentage of rhesus LCV LCL-specific CD8 T cells after
vaccination, but the difference did not reach statistical significance
(p=0.065 by T-test).
We did not observe CD4 or CD8 T cell responses to rhesus
LCV gp350 in monkeys after vaccination using LCLs as antigen
presenting cells, except for one animal that had an increase in
rhesus LCV LCL-specific cytokine positive CD4 T cell response
after vaccination with VRP-gp350 (Fig. 5). This is not surprising
since we were unable to detect rhesus LCV gp350 in LCLs by
immunoblot (data not shown). Therefore, we looked for T cells
responses to rhesus LCV gp350 by infecting LCLs with either
MVA-gp350 (which expresses rhesus LCV gp350) or wild-type
MVA and used these LCLs as antigen presenting cells. We did not
detect an increase in rhesus LCV gp350-specific PBMCs from
animals vaccinated with soluble gp350 or VRP-gp350 (data not
shown), even though MVA-gp350 expresses the glycoprotein
(Fig. 1). It is possible that a different method to present gp350 to
PBMCs would have been more effective; nonetheless, these data
suggest that soluble gp350 or VRP-gp350 did not induce a
significant increase in cellular immune responses in monkeys.
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from rhesus LCV better than VRP-gp350, or the
combination of VRP-gp350, VRP-EBNA-3A, and VRP-
EBNA-3B
A challenge inoculum of rhesus LCV was titered in LCV
seronegative rhesus monkeys. Five animals were initially given 14
TID50 (infectious dose of virus needed to transform 50% of wells of
cells in vitro) of rhesus LCV by application of virus to the throat
and all animals seroconverted. Based on these results, 10 weeks
after the last vaccination, animals were challenged by the oral
route with 50 TID50 of rhesus LCV.
Antibody to rhesus LCV viral capsid antigen (VCA) was detected
after challenge with rhesus LCV in all 4 animals that received PBS
Figure 3. Expression of EBNA-3A and EBNA-3B in transfected and latently infected cells. (A) Cos cells transfected with pSGrhEBNA3A1
and pSGrhEBNA3A1-del express EBNA-3A beginning at the first methionine without (lane 2) or with (lane 3) a deletion in the putative RBP-Jk binding
site, respectively. Cos cells transfected with pSGrhEBNA3A2 and pSGrhEBNA3A2-del express EBNA-3A beginning at the second methionine without
(lane 4) or with (lane 5) a deletion in the putative RBP-Jk binding site, respectively. Cos cells were transfected with pSGrhEBNA3B and pSGrhEBNA3B-
del, with a deletion in the putative RBP-Jk binding site (lanes 6 and 7, respectively). Cos cells were transfected with empty vector (pSG5, lane 8). (B)
Detection of EBNA-3A in Vero cells infected with VRP-EBNA-3A, or in LCL8664 cells and in a rhesus monkey LCL (LCL-V). Arrow indicates location of
EBNA-3A. (C) Detection of EBNA-3B in Vero cells infected with VRP-EBNA-3B, or in LCL8664 cells and LCL-V. Arrow indicates location of EBNA-3B.
Additional bands noted in cells infected with VRP expressing EBNA-3A or -3B are likely due to overexpression of the protein.
doi:10.1371/journal.ppat.1002308.g003
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solublegp350 and 3 of 4 animals that received a combination of VRP-
gp350, VRP-EBNA-3A, and VRP-EBNA-3B developed antibody to
rhesus LCV VCA after challenge (Fig. 6). Interestingly, seroconver-
sion was delayed to week 10 after challenge in the 2 animals that
received soluble gp350 that became infected, while seroconversion
occurred in weeks 3 to 8 in most of the other vaccine groups.
Like EBV, rhesus LCV DNA is present at very low or
undetectable copy numbers in PBMCs of healthy animals infected
in the past, but is usually detected in the blood after initial infection
[31]. Within 6 weeks after challenge, rhesus LCV DNA was
detected in PBMCs in 2 of 4 animals that received soluble gp350
and in 3 of 4 animals that received a combination of VRP-gp350,
VRP-EBNA-3A,and VRP-EBNA-3BorPBS(Fig.7).All4animals
that received VRP-gp350 had detectable rhesus LCV DNA.
To further verify that animals were protected from infection after
challenge we tested PBMCs from animals for rhesus LCV EBER1.
EBER1 is present inthousands of copies invirus-infected B cells and
is usually detected in the blood for life after infection of rhesus
monkeys [35]. After challenge, rhesus LCV EBER1 was detected in
PBMCs in 2 of 4 animals that received soluble gp350 and in 3 of 4
animalsthat receivedthecombinationofVRP-gp350,VRP-EBNA-
3A, and VRP-EBNA-3B (Fig. 8). One animal that received the
VRP-gp350, VRP-EBNA-3A, and VRP-EBNA-3B combination
had a single positive level of EBER1 in the blood at 3 weeks after
challenge and subsequently remained EBER1 negative. In contrast,
all 4 animals that received VRP-gp350 or PBS had detectable
EBER1 in the blood after challenge. Thus, all animals that
seroconverted were positive for LCV EBER1.
In summary, animals receiving soluble gp350 had the best level
of protection after challenge with the fewest numbers of animals
with rhesus LCV DNA or rhesus LCV RNA in the blood and the
lowest rate of seroconversion after challenge, while animals that
received the combination of VRP-gp350, VRP-EBNA-3A, and
VRP-EBNA-3B had the next best level of protection.
Analysis of fever, lymph node swelling, liver function tests, and
CD4 to CD8 ratios after challenge did not show discernable
differences in animals that received different vaccines or control PBS
Figure 4. Detection of gp350 antibody by luciferase immunoprecipitation assay in rhesus monkeys immunized with soluble gp350,
VRP-gp350, a combination of VRP-350, VRP-EBNA-3A, and VRP-EBNA-3B, or PBS before challenge with wild-type virus. gp350
antibody levels in naturally infected monkeys are shown. Antibody levels are measured as luminometer units. Cut off value is shown as horizontal
dotted line, which was determined as the mean +2 standard deviations of the blank signal (open circles). Horizontal bars indicate geometric mean,
asterisks indicate p,0.05 (Mann-Whitney’s U-test), NS indicates not significant.
doi:10.1371/journal.ppat.1002308.g004
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numbers of animals, all animals were all ,3y e a r so l d( a n dE B V
infectious mononucleosis is rare in young children), and variability in
animals after infection has been reported previously [19].
Animals vaccinated with recombinant soluble gp350
have the lowest rhesus LCV loads at 23 months after
infection with rhesus LCV compared with the other
vaccines, and comparable viral loads to those vaccinated
with the combination of VRP-gp350, VRP-EBNA-3A, and
VRP-EBNA-3B at 34 months
PBMCs were obtained from each of the vaccinated animals at
23 and 34 months after challenge. Using real time PCR with the
rhesus LCV DNA EBER1 probe, we were only able to detect
rhesus LCV DNA in PBMCs from 1 of the 16 animals 23 months
after challenge (data not shown). Therefore, we developed a more
sensitive real time PCR assay using IR1 DNA (corresponding to
the Bam HI W repeats of EBV) that are present at 5.7 copies in the
rhesus LCV genome [21]. Using the more sensitive real time PCR
assay we were able to detect rhesus LCV DNA in 5 of 5 monkeys
that had been naturally infected (data not shown). As expected we
were unable to detect rhesus LCV DNA in animals that had been
protected from challenge, therefore those animals were excluded
from further analyses to avoid skewing the results. At 23 months
after challenge, using the more sensitive real time PCR test, the
mean rhesus LCV DNA copy number was 15 copies per 10
6 cells
for animals vaccinated with soluble gp350, 3,986 for animals that
Figure 5. Detection of rhesus LCV-specific CD4 and CD8 T cell responses to gp350 or EBNA-3A and EBNA-3B in rhesus monkeys.
Animals were immunized with soluble gp350, VRP-gp350, a combination of VRP-gp350, VRP-EBNA-3A, and VRP-EBNA-3B, or PBS before challenge
with wild-type virus. Pre indicates PBMCs obtained before vaccination; post indicates PBMCs obtained after vaccination.
doi:10.1371/journal.ppat.1002308.g005
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VRP-EBNA-3B, 3,663 for animals receiving VRP-gp350, and
1,504 for animals that received PBS (Fig. 9A). At 34 months after
challenge, the mean rhesus LCV DNA copy number was 120
copies per 10
6 cells for animals vaccinated with soluble gp350, 0
for animals that received the combination of VRP-gp350, VRP-
EBNA-3A, and VRP-EBNA-3B, 3,605 for animals receiving
VRP-gp350, and 9,271 for animals that received PBS (Fig. 9B).
Thus, the rhesus LCV DNA copy number was lowest in animals
vaccinated with soluble gp350 at 23 months after challenge, and
was similar to the copy number in animals that received the
combination of VRP-gp350, VRP-EBNA-3A, and VRP-EBNA-
Figure 6. Detection of antibody to rhesus LCV VCA in monkeys immunized with soluble gp350, VRP-gp350, a combination of VRP-
350, VRP-EBNA-3A, and VRP-EBNA-3B, or PBS.
doi:10.1371/journal.ppat.1002308.g006
Figure 7. Detection of rhesus LCV DNA in the blood of monkeys immunized with soluble gp350, VRP-gp350, a combination of VRP-
350, VRP-EBNA-3A, and VRP-EBNA-3B, or PBS. Real time PCR was performed using a probe that detects EBER1 DNA.
doi:10.1371/journal.ppat.1002308.g007
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rhesus LCV DNA was detected 23 or 34 months after challenge in
1 of 2 animals that received soluble gp350, 2 of 3 animals that
received the combination of VRP-gp350, VRP-EBNA-3A, and
VRP-EBNA-3B, 4 of 4 animals that received VRP-gp350, and 3 of
4 animals that received PBS.
Discussion
Two different types of vaccines have been developed to prevent
disease and limit primary infection with EBV. Soluble EBV gp350
reduced the rate of infectious mononucleosis by 78% in young
adults [11]. Alternatively, induction of cellular immunity to
EBNA-3 has been proposed to limit the events occurring
immediately after primary infection including virus replication in
the throat and the expansion of virus-infected B cells [37]. Prior
studies have shown that EBNA-3 epitopes are primary targets for
EBV-specific CTLs in healthy persons, and therefore an EBV
vaccine containing EBNA-3 epitopes has been proposed [38,39].
A peptide corresponding to EBNA-3A elicited peptide-specific T
cell responses in EBV-seronegative human volunteers; 4 of 4
seronegative volunteers seroconverted to EBV asymptomatically,
while 1 of 2 placebo recipients infected with EBV developed
infectious mononucleosis [16]. Since rhesus LCV is considered one
of the best animal models for EBV infection, we compared rhesus
LCV soluble gp350 with VRPs expressing gp350 or VRPs
expressing a combination of gp350, EBNA-3A and EBNA-3B.
Animals received three doses of the vaccines at 0, 4, and 12 weeks.
We found that rhesus LCV soluble gp350 induced better
protection against challenge virus than VRPs expressing a
combination of gp350, EBNA-3A and EBNA-3B.
Animals vaccinated with soluble gp350 produced the highest
levels of antibody to the glycoprotein and these levels were higher
than those seen in monkeys naturally infected with rhesus LCV.
Prior studies have shown that antibody to gp350 is likely the
predominant component of neutralizing antibody to EBV
[40,41,42]. In addition gp350 induces antibody-dependent cellular
cytotoxicity which may also be important in controlling EBV
infection [43]. Animals vaccinated with VRP expressing gp350, or
VRPs expressing gp350, EBNA-3A, and EBNA-3B developed
lower levels of antibody to gp350 and had less protection against
acute infection than animals that received soluble gp350. Thus,
the high levels of antibody to gp350 are likely important for
protection against acute infection with rhesus LCV.
We compared soluble rhesus LCV gp350 with VRPs expressing
gp350 with the expectation that expression of the viral
glycoprotein in cells infected with VRPs might enhance the
immunogenicity of gp350 beyond its ability to induce antibody.
Animal studies have shown that neutralizing antibody to gp350
alone does not always correlate with protection from disease.
When cottontop tamarins were vaccinated with replication-
defective adenovirus expressing gp350, non-neutralizing antibody
to gp350 was induced, but the animals were protected against
lymphoma [7]. In contrast, when cottontop tamarins were
vaccinated with gp350 in liposomes, high titers of neutralizing
antibodies were induced, but the animals were not always
Figure 8. Detection of rhesus LCV EBER1 in the blood of monkeys immunized with soluble gp350, VRP-gp350, a combination of
VRP-350, VRP-EBNA-3A, and VRP-EBNA-3B, or PBS. RNA was isolated from PBMCs and reverse transcription was performed followed by real
time PCR with a probe that detects EBER1 DNA.
doi:10.1371/journal.ppat.1002308.g008
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from development of lymphoma, rather than protection from
infection. Immunization of common marmosets with gp350 in
alum resulted in neutralizing antibodies in some animals, but
protection from infection (defined by absence of seroconversion
after challenge) did not correlate with the presence of neutralizing
antibodies [45]. Somewhat surprisingly we found that rhesus LCV
soluble gp350 induced better protection against challenge virus
than VRP expressing gp350. Animals vaccinated with VRP
expressing gp350 had antibody to the glycoprotein at levels
comparable to animals naturally infected with rhesus LCV;
however, the levels were significantly lower than in animals
vaccinated with soluble gp350.
Animals vaccinated with alphavirus VRPs expressing EBNA-3A
and EBNA-3B developed CD4 and CD8 cell responses to these
proteins, while those vaccinated with VRPs expressing gp350 did
not have detectable cellular responses to the glycoprotein. It is
possible that the different methods used to present these antigens
(LCLs naturally expressing EBNA-3A and EBNA-3B versus cells
infected with MVA expressing gp350) could be responsible for
these differences. Alphavirus VRPs target dendritic cells, which
are highly efficient antigen presenting cells, and are effective for
Figure 9. Detection of rhesus LCV DNA in the blood of monkeys immunized with soluble gp350, VRP-gp350, a combination of VRP-
350, VRP-EBNA-3A, and VRP-EBNA-3B, or PBS and challenged with rhesus LCV. Blood was obtained 23 (A) and 34 months (B) after
challenge. Real time PCR was performed using a probe that detects rhesus LCV IR1 (corresponding to the EBV Bam HI W repeat) DNA. Horizontal lines
indicate mean values.
doi:10.1371/journal.ppat.1002308.g009
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that EBV EBNA-3A, EBNA-3B, and EBNA-3C are the main
targets of CD8 T cells in humans, while EBV EBNA-1 is the
principal target of CD4 T cells (reviewed in [12]). While EBV
gp350-specific CD8 T cells have been detected in patients during
infectious mononucleosis [47] and gp350-specific CD4 T cells
have been detected in healthy EBV carriers [48,49], the level of
these T cells has not been quantified relative to those against
EBNA-3. In general, the level of T responses to structural proteins
is generally lower than that to latent proteins in healthy EBV
carriers (reviewed in [12]).
After challenge of animals with rhesus LCV, animals vaccinated
with soluble rhesus LCV gp350 had the best level of protection
based on levels of rhesus LCV DNA or RNA in the blood and
lower rates of seroconversion. While animals that received VRP-
gp350, VRP-EBNA-3A, and VRP-EBNA-3B had the next best
level of protection from challenge and might have better
protection from reactivation, than those receiving the other
vaccine candidates, we could not test for protection against
reactivation with the small number of animals in the current study.
Although soluble gp350 induced the highest levels of antibody to
gp350 and the best protection from acute infection, addition of
potent EBV-specific T cell responses in combination with high
levels of antibody might enhance the effectiveness of an EBV
vaccine.
Although an ideal vaccine would protect from infection with
EBV, a vaccine that reduces the EBV DNA load might also be
useful. The EBV DNA load is a predictor for development of
certain EBV-associated malignancies [50]. EBV DNA is increased
in the blood of transplant recipients prior to the development of
EBV post-transplant lymphoproliferative disease [51], and ritux-
imab which lowers the viral load in the blood likely reduces the
rate of post-transplant lymphoproliferative disease [52]. Patients
with primary EBV infection after transplantation have high viral
loads, and a 24-fold increased risk of post-transplant lymphopro-
liferative disease compared with seropositive transplant recipients
[53]. Similarly, patients with HIV who progressed to B cell
lymphoma had elevated levels of EBV in PBMCs and the level
increased several months before developing lymphoma [54]. In
order to determine if our vaccine reduced the level of rhesus LCV
DNA in the blood, we developed a more sensitive assay for
detection of viral DNA. With this assay we found that animals
vaccinated with soluble gp350 that became infected with rhesus
LCV after challenge had lower levels of rhesus LCV DNA in
PBMCs at 23 and 34 months compared with animals that received
vaccine control (PBS). Taken together these finding suggest that an
EBV vaccine that reduces the viral load after infection might also
reduce the risk for development of certain EBV-associated
malignancies.
In summary, our findings indicate that a subunit vaccine that
induces primarily humoral, rather than cellular immunity can
result in a low virus load in animals that develop breakthrough
infection after challenge with wild-type virus. At 23 months after
challenge, animals vaccinated with soluble gp350 that became
infected with rhesus LCV had $100-fold lower levels of rhesus
LCV DNA in PBMCs than those vaccinated with VRP-gp350, or
the combination of VRP-gp350, VRP-EBNA-3A, and VRP-
EBNA-3B. Rhesus LCV DNA was still lower in PBMCs from
animals vaccinated with soluble gp350 at 34 months after
challenge compared with animals that received PBS. Thus,
antibodies to a viral glycoprotein before challenge likely alter the
primary infection in such a way as to result in a lower viral load
years later. While the largest EBV subunit vaccine study
performed to date showed that soluble gp350 protected against
infectious mononucleosis, breakthrough infection still occurred;
however, the authors did not report on the level of EBV DNA in
the blood after breakthrough infection [11]. Based on our data, as
well as observations of EBV DNA in PBMCs in certain
malignancies, future EBV vaccine studies should test the ability
of the vaccine to reduce viral loads in persons that become
infected.
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